Branded

JERUSALEM — Teva Pharmaceutical Industries on Thursday announced that the Food and Drug Administration has granted full approval of Synribo (omacetaxine mepesuccinate) for injection.

The drug is indicated for adult patients with chronic phase or accelerated phase chronic myeloid leukemia with resistance and/or intolerance to two or more tyrosine kinase inhibitors.

SILVER SPRING, Md. — After meeting for two days earlier this week, the Food and Drug Administration's Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 16-9 against changing the label of naproxen to highlight a lower cardiovascular risk profile as compared to other NSAIDs, according to published reports. 

Those advisory panels who voted against the change felt the data were insufficient to say naproxen was safer than other NSAIDs.

DUBLIN — Mallinckrodt and Cadence Pharmaceuticals on Tuesday announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis, which represents a 32% premium to the trailing 30-trading-day volume weighted average price of $10.62 per share for Cadence Pharmaceuticals.

WASHINGTON — America’s biopharmaceutical research companies currently are developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide, the Pharmaceutical Research and Manufacturers of America announced Tuesday. These medicines in development — all either in clinical trials or under review by the Food and Drug Administration — include 30 for type 1 diabetes, 100 for type 2 and 52 for diabetes-related conditions.

ARLINGTON, Va. — The Healthcare Distribution Management Association on Saturday announced the promotion of six staff members:

ATLANTA — According to last week’s FluView report, released Friday, influenza activity remains elevated nationally. Flu activity is likely to continue for several more weeks, the Centers for Disease Control and Prevention concluded.

For the week of Jan. 26 through Feb. 1, the national proportion of people seeing their healthcare provider for influenza-like illness decreased slightly for the fifth week, but remains above the national baseline. All 10 regions continue to report ILI activity above their region-specific baseline level. 

WASHINGTON — The United States Hispanic Chamber of Commerce on Thursday welcomed Boehringer Ingelheim Pharmaceuticals to its family of corporate members as a strategic partner. "Boehringer Ingelheim's commitment to educating the Hispanic community on the impact of chronic disease is particularly noteworthy," the group noted. "Their dedication to community health was highlighted during last year's launch of a highly successful initiative, in partnership with Univision, that promoted best practices for preventing and treating diabetes.

Selecting a doctor can be a frustrating process filled with too many unknowns, especially in today’s evolving landscape. Looking to help patients take the guesswork out of finding the ideal doctor, Vitals has developed online tools at Vitals.com to give patients visibility into quality, cost and availability.